15:50:22 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-12 Kvartalsrapport 2024-Q3
2024-07-25 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-11 Årsstämma 2024
2024-02-22 Halvårsutdelning AZN 20.65
2024-02-08 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-10 Halvårsutdelning AZN 9.64
2023-07-28 Kvartalsrapport 2023-Q2
2023-04-27 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-23 Halvårsutdelning AZN 20.69
2023-02-09 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Halvårsutdelning AZN 9.49
2022-07-29 Kvartalsrapport 2022-Q2
2022-04-29 Kvartalsrapport 2022-Q1
2022-04-29 Årsstämma 2022
2022-02-24 Halvårsutdelning AZN 18
2022-02-10 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-12 Halvårsutdelning AZN 7.72
2021-07-29 Kvartalsrapport 2021-Q2
2021-05-11 Årsstämma 2021
2021-04-30 Kvartalsrapport 2021-Q1
2021-02-25 Halvårsutdelning AZN 15.76
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-13 Halvårsutdelning AZN 7.87
2020-07-30 Kvartalsrapport 2020-Q2
2020-04-29 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 Halvårsutdelning AZN 18.32
2020-02-14 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-08 Halvårsutdelning AZN 8.49
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-26 Kvartalsrapport 2019-Q1
2019-04-26 Årsstämma 2019
2019-02-28 Halvårsutdelning AZN 17.46
2019-02-14 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-09 Halvårsutdelning AZN 7.92
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-18 Kvartalsrapport 2018-Q1
2018-05-18 Årsstämma 2018
2018-02-15 Halvårsutdelning AZN 14.97
2018-02-02 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-08-10 Halvårsutdelning AZN 7.4
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-16 Halvårsutdelning AZN 16.57
2017-02-02 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-11 Halvårsutdelning AZN 7.81
2016-07-28 Kvartalsrapport 2016-Q2
2016-04-29 Kvartalsrapport 2016-Q1
2016-04-29 Årsstämma 2016
2016-02-18 Halvårsutdelning AZN 16.26
2016-02-04 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-13 Halvårsutdelning AZN 7.71
2015-07-30 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-04-24 Årsstämma 2015
2015-02-19 Halvårsutdelning AZN 15.62
2015-02-05 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-13 Halvårsutdelning AZN 6.2
2014-07-31 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-24 Årsstämma 2014
2014-02-19 Halvårsutdelning AZN 12.41
2014-02-06 Bokslutskommuniké 2013
2013-10-31 Kvartalsrapport 2013-Q3
2013-08-14 Halvårsutdelning AZN 5.92
2013-08-01 Kvartalsrapport 2013-Q2
2013-08-01 Analytiker möte 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-13 Halvårsutdelning AZN 12.08
2013-01-31 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-10-25 Analytiker möte 2012
2012-08-08 Halvårsutdelning AZN 6.26
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Kvartalsrapport 2012-Q1
2012-04-26 Årsstämma 2012
2012-02-15 Halvårsutdelning AZN 13.21
2012-02-02 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-03 Halvårsutdelning AZN 5.33
2011-07-28 Kvartalsrapport 2011-Q2
2011-04-28 Årsstämma 2011
2011-04-28 Kvartalsrapport 2011-Q1
2011-02-02 Halvårsutdelning AZN 11.99
2011-01-27 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-04 Halvårsutdelning AZN 5.12
2010-07-29 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-02-03 Halvårsutdelning AZN 12.43
2010-01-28 Bokslutskommuniké 2009
2009-10-29 Kvartalsrapport 2009-Q3
2009-08-05 Halvårsutdelning AZN 4.41
2009-07-30 Kvartalsrapport 2009-Q2
2009-04-30 Kvartalsrapport 2009-Q1
2009-04-30 Årsstämma 1
2009-02-04 Halvårsutdelning AZN 12.02
2008-08-06 Halvårsutdelning AZN 3.34
2008-02-06 Halvårsutdelning AZN 8.61
2007-08-08 Halvårsutdelning AZN 3.49
2007-02-07 Halvårsutdelning AZN 8.6
2006-08-09 Halvårsutdelning AZN 3.6
2006-02-08 Halvårsutdelning AZN 7.02
2005-08-10 Halvårsutdelning AZN 2.99
2005-02-09 Halvårsutdelning AZN 4.497
2004-08-11 Halvårsutdelning AZN 2.2
2004-02-18 Halvårsutdelning AZN 3.91
2003-08-20 Halvårsutdelning AZN 2.07
2003-02-19 Halvårsutdelning AZN 3.99
2002-08-21 Halvårsutdelning AZN 2.21
2002-02-20 Halvårsutdelning AZN 5.01
2001-08-22 Halvårsutdelning AZN 2.44
2001-02-21 Halvårsutdelning AZN 4.49
2000-09-04 Halvårsutdelning AZN 2.1
2000-03-08 Halvårsutdelning AZN 4.01
1999-09-06 Halvårsutdelning AZN 1.89
1999-04-01 Split AZN 1:0.5045
1997-05-26 Split AZN 1:2
1993-06-14 Split AZN 1:5
1987-06-04 Split AZN 1:2

Beskrivning

LandStorbritannien
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AstraZeneca är ett globalt läkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även aktiva inom autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamt inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien.
2022-10-31 10:00:38

Depth and breadth of data underscore commitment to addressing areas of high unmet need in cardiorenal and rare nephrology diseases.

AstraZeneca will present over 60 abstracts across its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio and from Alexion, AstraZeneca's Rare Disease group, at the American Society of Nephrology (ASN) Kidney Week from 3-6 November 2022 and the American Heart Association (AHA) Scientific Sessions occurring 5-7 November 2022.

With robust science across both medical congresses, AstraZeneca demonstrates its ambition to fundamentally transform cardiorenal care and advance patient outcomes by unravelling the underlying causes of disease, developing diagnostic strategies and delivering innovative, life-changing solutions for the millions of people affected by this interconnected spectrum of diseases. Additionally, Alexion will present data highlighting scientific advancements that further the understanding of complement inhibition in the treatment of rare nephrology diseases.

Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "Scientific advances are revealing the connection between cardiovascular, renal and metabolic diseases, helping to drive earlier diagnosis and opportunities for integrated treatment approaches. We look forward to sharing insights across our portfolio, including our early science targeting specific disease drivers and data from both the DELIVER and DAPA-CKD Phase III trials which build on the science demonstrating the unique cardiorenal protection and mortality benefit of Farxiga."

Farxiga in heart failure (HF) - setting a new standard in HF management

New late-breaking data from the DELIVER Phase III trial presented at AHA assess the effects of Farxiga on health status, on patients with recurrent cardiac events, the impact based on use of other therapies, on gender or race and more[1-5]. These data reinforce the joint 2022 guidelines issued by AHA, the American College of Cardiology (ACC) and the Heart Failure Society of America (HFSA), recommending earlier diagnosis and earlier initiation of guideline-directed medical treatment in patients with HF[6]. Altogether, the pooled analysis from the Phase III DELIVER and DAPA-HF trials underpins the role of Farxiga in clinical practice as a treatment that can be initiated right away while waiting for ejection fraction (EF) to be measured and that showed mortality benefit across the full EF range[7].

Farxiga in chronic kidney disease (CKD) - reinforcing leadership in CKD

New subgroup data from the DAPA-CKD Phase III trial assess effect in patients with microalbuminuria, how Farxiga use impacts hospital admissions and healthcare utilisation and highlights AstraZeneca's commitment to help prevent or slow the progression of CKD in this large patient population[8-10]. These data presented at ASN also support recent updates to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which highlight the need for preventive treatment strategies that reduce the risk of adverse kidney and cardiovascular (CV) outcomes[11].

REVEAL-CKD - emphasising the need for earlier diagnosis

REVEAL-CKD data also shed light on the importance of earlier diagnosis of CKD, with the prevalence of undiagnosed CKD continuing to rise. REVEAL-CKD further demonstrated that once a diagnosis was made, patients did receive timely CKD monitoring and management of their disease, leading to patient benefits[12].

Lokelma - advancing proactive hyperkalaemia (HK) management

New Lokelma data from the comprehensive CRYSTALIZE evidence programme, which is poised to disrupt the current management of HK, highlight the common and detrimental effects of renin-angiotensin-aldosterone system inhibitors (RAASi) down titration and/or discontinuation, resulting in suboptimal care of patients with CKD and/or HF, as well as patient preference amongst potassium (K[+]) binder treatments[13][,14]. The 2020 and 2021 KDIGO[15,16], 2021 European Society of Cardiology (ESC)[17] and 2022 AHA/ACC/HFSA guidelines[6] recognise novel K[+] binders like Lokelma as an important management option to optimise RAASi therapy, a group of medicines key to slowing progression and reducing mortality risk in patients with CKD and/or HF.

Compass Programme - highlighting the importance of earlier diagnosis in hereditary amyloid transthyretin amyloidosis (ATTR)

Findings from the Compass Programme provide important insights on genetic testing for ATTR. Amyloidosis is progressive and may be systemic, affecting different organs within the body (i.e., heart, kidneys, peripheral nerves)[18].

Amyloidosis diseases can be complex, difficult to diagnose and, in many cases, fatal if left untreated[19-21]. AstraZeneca, in partnership with Ionis, and Alexion, are advancing multiple assets and novel science in amyloidosis, including treatments for ATTR, cardiomyopathy (CM) and polyneuropathy (PN), as well as amyloid light chain (AL) amyloidosis.

Rare nephrology - expanding our leadership in complement inhibition

Alexion will present an analysis from the global atypical hemolytic uremic syndrome (aHUS) registry involving long-term outcomes in patients who are treated with Soliris, a characterisation of patients with thrombotic microangiopathy and triggering or associated events from the aHUS registry, as well as a tool (PLASMIC score) that may aid in the diagnosis of aHUS[22-24].[ ]

Alexion is also expanding its focus in rare nephrology with multiple assets in its clinical development programmes - including Ultomiris (a C5 inhibitor) and ALXN2050 (an oral factor D inhibitor) - which are being investigated as potential treatments for proliferative lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN). The presentations at ASN, which include clinical trial and real-world data across several therapeutic areas, will help to advance the understanding of these rare nephrology diseases and foster scientific exchange[22-26].[ ]

AstraZeneca abstracts at ASN Kidney Week 2022 include:

Lead author Abstract title Presentation details
Farxiga
Schechter M Dapagliflozin Oral PresentationCKD: Clinical Outcomes,
effect on Trials, Mechanistic InsightsNovember 4, 2022
hospital 16:30-18:00Session Room: W307
admissions in
patients with
chronic kidney
disease: A post
hoc analysis of
the DAPA-CKD
trial
Vart P Efficacy and PosterCKD: Clinical Trials and
safety of PharmacoepidemiologyNovember 5, 2022 10:00
dapagliflozin in -12:00 Poster #: SA-PO889
black vs. white
patients with CKD
Vart P Effects of Oral PresentationHigh-Impact CKD Potpourri:
dapagliflozin on Something for EveryoneNovember 5, 2022 16:30
anaemia in -18:00Session Room: W307
patients with or
without type 2
diabetes: A pre
-specified
analysis of the
DAPA-CKD trial
Jongs N Consistent PosterCKD: Clinical Trials and
benefits of PharmacoepidemiologyNovember 5, 2022 10:00
dapagliflozin on -12:00 Poster #: SA-PO886
kidney endpoints
defined by
different eGFR
thresholds: A
prespecified
analysis from
DAPA-CKD
Davis J Extrapolation of PosterCKD: Clinical Trials and
DAPA-CKD trial PharmacoepidemiologyNovember 5, 2022 10:00
endpoints in a -12:00 Poster #: SA-PO888
broad urine
albumin
creatinine ratio
population
McEwan P Translating the PosterCKD: Clinical Trials and
findings of DAPA PharmacoepidemiologyNovember 5, 2022 10:00
-CKD to -12:00 Poster #: SA-PO887
reductions in
healthcare
resource
utilization from
a global
perspective
Wittbrodt E Early PosterCKD: Epidemiology, Risk Factors,
dapagliflozin PreventionNovember 3, 2022 10:00-12:00
utilization for Poster #: TH-PO855
CKD treatment in
the United States
Leon SJ Association PosterHypertension and CVD: Epidemiology,
between CKD Risk Factors, PreventionNovember 3, 2022
progression and 10:00-12:00 Poster #: TH-PO630
heart failure: A
retrospective
cohort study
Heerspink HJ Effects of PosterCKD: Clinical Trials and
dapagliflozin in Pharmacoepidemiology November 5, 2022 10:00
patients without -12:00Poster #: SA-PO885
diabetes and with
microalbuminuria:
An exploratory
analysis from the
DAPA-CKD trial
Sisk R A global PosterDiabetic Kidney Disease: Clinical -
validation of a IINovember 3, 2022 10:00-12:00 Poster #: SA
minimal-resource -PO283
pre-screening
model for reduced
kidney function
in patients with
type 2 diabetes
Shoichi M    Impact of urinary PosterCKD: Epidemiology, Risk Factors,
protein Prevention November 3, 2022 10:00-12:00
examination on Poster #: TH-PO883
early diagnosis
of CKD: A
nationwide
hospital-based
observational
study in Japan,
REAL-CKD
Heerspink H Correlation Poster Diabetic Kidney Disease: Clinical
between November 3, 2022 10:00-12:00 Poster #: TH
albuminuria and -PO233
echocardiographic
(echo)
abnormalities in
individuals with
type 2 diabetes
(T2D): Insights
from the Take
Care of Me (TCoM)
program
McCausland F Dapagliflozin and PosterLate-Breaking Clinical Trials
kidney outcomes (Posters)November 3, 2022 10:00-12:00
in patients with Poster #: TH-PO992
heart failure Location: West Exhibit Hall E
with mildly
reduced or
preserved
ejection
fraction: Results
from DELIVER
Dapagliflozin/
Metformin
Santos Cardiorenal PosterHypertension and CVD: Epidemiology,
-Araúijo C syndrome and Risk Factors, PreventionNovember 3, 2022
death risk in 10:00-12:00Poster #: TH-PO628
patients with
heart failure or
chronic kidney
disease: An
urgent call for
action
Santos Cardiorenal PosterHypertension and CVD: Epidemiology,
-Araúijo C syndrome and Risk Factors, PreventionNovember 3, 2022
kidney disease 10:00-12:00Poster #: TH-PO627
progression in
patients with
heart failure or
CKD: An urgent
call for action
Verinurad
(RDEA3170)
Halperin Urate regulates PosterCKD: PathobiologyNovember 4, 2022
Kuhns V mitochondrial 10:00-12:00 Poster #: FR-PO996
function in a
URAT1 dependent
manner in renal
epithelial cells
Lokelma
Wheeler D APPETIZE: Poster Fluid, Electrolyte, and Acid-Base
Palatability of Disorders: Clinical November 4, 2022 10:00
and preference -12:00 Poster #: FR-PO552
for potassium
binders in
patients with CKD
and hyperkalaemia
Ni Z DIALIZE China: A Oral PresentationDialysis: Patient-Centered
phase 3b study to Interventions and OutcomesNovember 3, 2022
reduce pre 16:30-18:00Session Room: W414
-dialysis
hyperkalaemia
with sodium
zirconium
cyclosilicate in
Chinese subjects
Hsia J A prospective, Abstract SupplementAbstract published in
real-world ASN's 2022 Abstract Supplement, available
evidence study of here: https://www.asn-online.org/abstracts/
hyperkalaemia
management
decision making:
Design of the
TRACK study
Bakris G Effects of sodium PosterFluid, Electrolyte, and Acid-Base
zirconium Disorders: ClinicalNovember 4, 2022 10:00
cyclosilicate -12:00Poster #: FR-PO550
(SZC) on CKD
progression:
Rationale and
design of the
phase 3 STABILIZE
-CKD trial
Ni Z Hyperkalaemia Poster Hemodialysis and Frequent Dialysis:
disease burden PotpourriNovember 5, 2022 10:00-12:00Poster
and dialysis #: SA-PO311
patterns in
Chinese
haemodialysis
patients: An
interim analysis
of the Precede-K
study
Zhao X Hyperkalaemia Abstract SupplementAbstract published in
prevalence, ASN's 2022 Abstract Supplement, available
practice pattern here: https://www.asn-online.org/abstracts/
and mortality in
Chinese
haemodialysis
patients:
Visualize-HD
study
Streja E Impact of PosterFluid, Electrolyte, and Acid-Base
hyperkalaemia on Disorders: Clinical November 4, 2022 10:00
mortality in -12:00Poster #: FR-PO544
patients with
advanced kidney
disease with or
without
haemodialysis:
Implications for
deferring
hemodialysis
initiation under
value-based
models
Rastogi A Persistent PosterFluid, Electrolyte, and Acid-Base
reduction in Disorders: Clinical November 4, 2022 10:00
RAASi therapy -12:00Poster #: FR-PO546
following an
episode of
hyperkalaemia
Zhou H Recurrent PosterFluid, Electrolyte, and Acid-Base
hyperkalaemia and Disorders: Clinical November 4, 2022 10:00
renin-angiotensin -12:00Poster #: FR-PO547
-aldosterone
system inhibitor
(RAASi) down
-titration in a
US integrated
healthcare system
An J Cardiorenal and PosterFluid, Electrolyte, and Acid-Base
mortality Disorders: ClinicalNovember 4, 2022 10:00
outcomes -12:00 Poster #: FR-PO548
associated with
renin-angiotensin
-aldosterone
system inhibitor
(RAASi)
discontinuation
after new-onset
hyperkalaemia
Marmol F Renal adaptation PosterFluid, Electrolyte, and Acid-Base
to increased Disorders: BasicNovember 3, 2022 10:00-12:00
fecal potassium Poster #: TH-PO305
excretion by
sodium zirconium
cyclosilicate
Marmol F Sodium zirconium PosterFluid, Electrolyte, and Acid-Base
cyclosilicate Disorders: Basic November 3, 2022 10:00
(SZC) binds -12:00Poster #: TH-PO304
ammonium (NH4+)
in the GI tract
Eichiro K Impact of chronic Poster
potassium binder Fluid, Electrolyte, and Acid-Base Disorders:
treatment on ClinicalNovember 4, 2022 10:00-12:00Poster
clinical outcome #: FR-PO549
in patients with
hyperkalaemia: A
nationwide
hospital-based
cohort study
General/Early
CVRM
Lal M Therapeutic PosterGlomerular Diseases: Podocyte
blocking of NPRC, BiologyNovember 4, 2022 10:00-12:00 Poster
a podocyte #: FR-PO696
-expressed
target, is kidney
protective in
ZSF1 rats
Svangård N Toward a model Abstract SupplementAbstract published in
-based patient ASN's 2022 Abstract Supplement, available
pre-selection here: https://www.asn-online.org/abstracts/
tool to identify
suspected
undiagnosed
albuminuria using
electronic health
records
Seth A TWEAK-Fn14 PosterCKD: Epidemiology, Risk Factors,
signalling in PreventionNovember 3, 2022 10:00-12:00Poster
mesangial cells #: TH-PO891
drives intrarenal
inflammation
during CKD
progression
Carracedo M APOL1 promotes Oral PresentationGlomerular Diseases: From
endothelial cell Bench to Bedside November 4, 2022 16:30
activation beyond -18:00 Session Room: W414
the glomerulus
Acoba D Kidney `pathway Abstract Supplement Abstract published in
orphan' genes as ASN's 2022 Abstract Supplement, available
an untapped here: https://www.asn-online.org/abstracts/
source of novel
biology and
disease
understanding
Woollard KJ Investigating Poster CKD: Pathobiology - INovember 4, 2022
lysozyme as a 10:00-12:00Poster #: FR-PO1008
mediator of
tubular
epithelial
inflammation: An
example of CKD
knowledge graph
target discovery
and validation
Tomaz D NLRP3 Poster AKI: Mechanisms - IINovember 4, 2022
inflammasome 10:00-12:00Poster #: FR-PO167
inhibition
decreases NETosis
in AKI
Zibotentan
(ZD4054)
Ahlström C SGLT2 inhibition Abstract Supplement Abstract published in
mitigates ASN's 2022 Abstract Supplement, available
intravascular here: https://www.asn-online.org/abstracts/
fluid retention
driven by an
endothelin A
receptor
antagonist
REVEAL-CKD
Tangri N REVEAL-CKD: PosterCKD: Epidemiology, Risk Factors,
Management and PreventionNovember 3, 2022 10:00-12:00Poster
monitoring of #: TH-PO889
patients with CKD
stage 3 in
France, Germany,
Italy, Japan and
the United States
Tangri N REVEAL CKD: PosterCKD: Epidemiology, Risk Factors,
Estimated Prevention November 3, 2022 10:00
glomerular -12:00Poster #: TH-PO888
filtration rate
(eGFR) decline
before and after
a CKD diagnosis
among patients
with CKD stage 3
Global aHUS
Registry
Siedlecki A Characterization PosterGlomerular Diseases: Clinical,
of patients with Outcomes, Trials - I [PO1303-1]November 3,
thrombotic 2022 10:00-12:00Poster #: TH-PO500
microangiopathy
and
triggering/associa
ted events: A
Global aHUS
Registry analysis
Greenbaum L Long-term PosterGlomerular Diseases: Clinical,
outcomes in Outcomes, Trials - I [PO1303-1]November 3,
eculizumab 2022 10:00-12:00Poster #: TH-PO502
-treated patients
enrolled in the
global aHUS
registry
Soliris and
Ultomiris
Uriol M PLASMIC score to PosterGlomerular Diseases: Clinical,
aid diagnosis of Outcomes, Trials - I [PO1303-1]November 3,
atypical 2022 10:00-12:00Poster #: TH-PO501
hemolytic
uremicsyndrome: A
post-hoc analysis
of data from C5
inhibitor trials
Ultomiris
Garlo K A phase 2 study PosterNovember 3, 2022 10:00-12:00Poster #:
evaluating the INFO34
efficacy and
safety of
ravulizumab in
patients with
immunoglobulin A
nephropathy
(IgAN) or
proliferative
lupus nephritis
(LN)
ALXN2050
Garlo K A phase 2 study PosterNovember 3, 2022 10:00-12:00Poster #:
evaluating the INFO33
efficacy and
safety of
ALXN2050, a
complement factor
D inhibitor, in
patients with
immunoglobulin A
nephropathy
(IgAN) or
proliferative
lupus nephritis
(LN)

ASN Kidney Week 2022 abstracts are available online (https://www.asn-online.org/abstracts/).

AstraZeneca abstracts at AHA Scientific Sessions 2022 include:

Lead author Abstract title Presentation details
Farxiga
Jhund P First and repeat Oral Presentation
episodes of In-depth and Fresh Look in Heart Failure
worsening heart TrialsNovember 6, 2022 8:36-8:46Session Room:
failure in N230B
patients with
heart failure
with mildly
reduced and
preserved
ejection
fraction: An
analysis of
Deliver
Bhatt A Impact of Oral Presentation Evolving Science in COVID
Coronavirus -19November 7, 2022 8:20-8:30 Session Room:
Disease-2019 on Main Event III
participants in
DELIVER
Kosiborod M The effects of Oral PresentationA Second Look at Practice
dapagliflozin on -Changing Heart Failure TrialsNovember 7, 2022
symptoms, 11:00-11:08Session Room: Main Event II
function and
quality of life
in patients with
heart failure and
mildly reduced or
preserved
ejection
fraction: Results
from the DELIVER
Trial
Yang M Baseline Oral PresentationA Second Look at Practice
characteristics, -Changing Heart Failure TrialsNovember 7, 2022
outcomes, and 11:08-11:16 Session Room: Main Event II
treatment
response to
dapagliflozin in
patients treated
with an MRA or
ARNI in DELIVER
Wang X Sex differences Oral PresentationA Second Look at Practice
in -Changing Heart Failure TrialsNovember 7, 2022
characteristics, 11:16-11:24Session Room: Main Event II
outcomes and
treatment
response with
dapagliflozin
across the range
of ejection
fraction in
patients with
heart failure
Butt J Differences in Oral PresentationA Second Look at Practice
clinical -Changing Heart Failure TrialsNovember 7, 2022
characteristics, 11:24-11:32Session Room: Main Event II
outcomes, and
treatment
response to
dapagliflozin
across the range
of ejection
fraction in Black
and White
patients with
heart failure: A
pooled analysis
of DAPA-HF and
DELIVER
Schechter M The effect of Virtual Poster - Available November 5-7,
dapagliflozin on 2022Poster #: VP345
hospital
admissions in
patients with
type 2 diabetes:
Post hoc analysis
of the DECLARE
-TIMI 58 trial
Bozkurt B Use of guideline PosterDrugs, Drugs and More Drugs in Heart
-directed medical Failure: Impact on OutcomesNovember 6, 2022
therapies after 10:30-11:30Poster #: SU2153
hospitalization
for heart
failure: Real
-world insights
from EVOLUTION HF
Berg D Serial assessment Oral SessionAdvances in Diabetes and Heart
of cardiac Failure: From Bench to Bedside November 6,
biomarkers and 2022 15:54-16:04Session Room: N231
risk of
cardiovascular
death or
hospitalization
for heart failure
in DECLARE-TIMI
58
Chung-Lieh Clinical Virtual Poster - Available November 5-7,
H utilization of 2022Poster #: VP347
natriuretic
peptide levels
independent of
WATCH-DM score
for heart failure
prediction in a
large-scale Asian
diabetic
population - A
multi-center
cohort study
Tsubota H Machine learning PosterPredicting Incident Diabetes and Its
models to predict ComplicationsNovember 6, 2022 10:30
development of -11:30Poster #: SU3000
CKD and/or HF in
early stages of
type 2 diabetes
patients
Kosiborod M Prevalence and PosterMechanisms and Treatments for Heart
correlates of Failure in DiabetesNovember 6, 2022 10:30
echocardiographic -11:30Poster #: SU3012
abnormalities in
type 2 diabetes:
Insights from
iCaReMe Global
Registry
Gupta K Health status Moderated PosterNovember 7, 2022 10:00
outcomes by race -10:05Poster #: MP186
in patients
treated with
sodium-glucose
cotransporter 2
inhibitors: A
pooled patient
-level meta
-analysis of
CHIEF-HF, DEFINE
-HF, and
PRESERVED-HF
Brilinta
Small A Development of a Oral Presentation November 6, 2022 12:10
novel polygenic -12:15Poster #: 554
risk score to
predict risk of
aortic stenosis
events
Ohman E Impact of Oral PresentationOptimal Management post
ticagrelor with PCI/ACS November 7, 2022 10:02-10:12Session
or without Room: Main Event III
aspirin on total
and recurrent
bleeding and
ischemic events
after PCI:
Results from the
TWILIGHT -
Recurrent Events
sub-study
Eplontersen
Bhatt K Genetic testing Moderated PosterNovember 5, 2022 11:00
for hereditary -12:00Poster #: SA2110
amyloid
transthyretin
amyloidosis:
Insights from the
Compass Program
Exenatide
Ostroff R Cardiometabolic Rapid Fire Oral PresentationUnderstanding and
disease protein Modifying Cardiovascular Risk in
signatures and DiabetesNovember 7, 2022 13:00-13:05Session
response to GLP-1 Room: Zone 3, Science & Technology hall, Level
receptor agonist 3
in the EXSCEL
clinical trial
Peters AE Proteomic Poster Biomarkers in Heart Failure: Prognostic
pathways across Indicators and Mechanistic ResearchNovember 6,
ejection fraction 2022 15:45-16:45Poster #: SU2183
categories in
heart failure: an
EXSCEL substudy
Edmonston D Metabolic Oral PresentationIntersection of Kidney and
profiles identify Heart Failure - Biomarkers, Treatment, and
distinct Outcomes in Patients with Cardiorenal
cardiorenal risk DiseaseNovember 6, 2022 17:00-17:10Session
factors in people Room: S101B
with diabetes
mellitus:
Insights from the
EXSCEL trial
Early R&D
Kardassis D Safety, Virtual Poster - Available November 5-7,
pharmacokinetics, 2022Poster #: VP26
and
pharmacodynamics
of AZD3366 alone
and in
combination with
aspirin and
ticagrelor in
healthy subjects
Varma V Identification of Virtual Poster - Available November 5-7,
response 2022Poster #: VP6
biomarkers and
signaling
pathways
associated with
the LOX-1
blockade by
MEDI6570 in type
2 diabetes
Hofherr A The PCSK9 Virtual Poster - Available November 5-7,
-targeted 2022Poster #: VP112
antisense
oligonucleotide
AZD8233 reduces
LDL-C, ApoB, and
Lp(a) in patients
with dyslipidemia
on statin
treatment - Data
from the phase 2b
ETESIAN study

AHA Scientific Sessions 2022 abstracts are available online (https://eppro02.ativ.me/src/EventPilot/php/express/web/planner.php?id=AHA22).

Notes

AstraZeneca in CVRM

Cardiovascular, Renal and Metabolism (CVRM), part of BioPharmaceuticals, forms one of AstraZeneca's main disease areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines for organ protection and improving outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CV health for millions of patients worldwide.

Alexion

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on haematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Contacts

For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).

References

1. Kosiborod MN, et al. The effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and mildly reduced or preserved ejection fraction: results from the DELIVER Trial. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
2. Jhund P, et al. First and repeat hospitalizations for heart failure in patients with heart failure with mildly reduced and preserved ejection fraction: An analysis of DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
3. Jhund P, et al. Baseline characteristics, outcomes, and treatment response to dapagliflozin in patients treated with an MRA or ARNI in DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
4. Solomon S, et al. Sex differences in characteristics, outcomes and treatment response with dapagliflozin across the range of ejection fraction in patients with heart failure: a pooled analysis of DAPA-HF and DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
5. Butt J, et al. Differences in clinical characteristics, outcomes, and treatment response to dapagliflozin across the range of ejection fraction in Black and White patients with heart failure: A pooled analysis of DAPA-HF and DELIVER. Presented at: American Heart Association (AHA) Scientific Sessions 2022, 5-7 November 2022, Chicago, Illinois, USA.
6. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032.
7. Jhund P, et al [Internet]. Dapagliflozin and outcomes across the range of ejection fraction in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. Nature Medicine. [cited 2022 Oct 11] Available from: https://www.nature.com/articles/s41591-022-01971-4
8. Davis J, et al. Extrapolation of DAPA-CKD trial endpoints in a broad urine albumin creatinine ratio population. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
9. Schechter M, et al. Dapagliflozin effect on hospital admissions in patients with chronic kidney disease: A post hoc analysis of the DAPA-CKD trial. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
10. McEwan P, et al. Translating the findings of DAPA-CKD to reductions in healthcare resource utilization from a global perspective. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
11. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group [Internet]. KIDGO 2022 clinical practice guideline for diabetes management in chronic kidney disease [cited 2022 Oct 11]. Available from: KDIGO-2022-Diabetes-Management-GL_Public-Review-draft_1Mar2022.pdf.   
12. Tangri N, et al. REVEAL-CKD: Management and monitoring of patients with CKD stage 3 in France, Germany, Italy, Japan, and the USA. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA
13. Ni Z, et al. DIALIZE China: A phase 3b study to reduce pre-dialysis hyperkalaemia with sodium zirconium cyclosilicate in Chinese subjects. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
14. Wheeler D, et al. APPETIZE: Palatability of and preference for potassium binders in patients with chronic kidney disease and hyperkalaemia. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
15. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int Suppl. 2020;98:S1-S115. 
16. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021; 99(3S):S1-S87. 
17. European Society of Cardiology [Internet]. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [cited 2022 Oct 11]. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehab368.
18. Bhatt K, et al. Genetic testing for hereditary amyloid transthyretin amyloidosis: Insights from the Compass Program. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
19. NORD [Internet]. Amyloidosis [cited 2022 Oct 11]. Available from: https://rarediseases.org/rare-diseases/amyloidosis/
20. Leukaemia and Lymphoma Society [Internet]. Amyloidosis fact [cited 2022 Oct 11]. Available from: https://llscorp.stg.lls.org/sites/default/files/2021-05/Amyloidosis_FINAL.pdf
21. Cedars Sinai [Internet]. Amyloidosis [cited 2022 Oct 11]. Available from: https://www.cedars-sinai.org/health-library/diseases-and-conditions/a/amyloidosis.html
22. Siedlecki A, et al. Characterization of patients with thrombotic microangiopathy and triggering/associated events: A global aHUS registry analysis. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
23. Greenbaum L, et al. Long-term outcomes in eculizumab-treated patients enrolled in the global aHUS registry. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
24. Uriol M, et al. PLASMIC score to aid diagnosis of aHUS: A post-hoc analysis of data from C5 inhibitor trials. Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
25. Garlo K, et al. A phase 2 study evaluating the efficacy and safety of ravulizumab in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN). Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.
26. Garlo K, et al. A phase 2 study evaluating the efficacy and safety of ALXN2050, a complement factor D inhibitor, in patients with immunoglobulin A nephropathy (IgAN) or proliferative lupus nephritis (LN). Presented at: American Society of Nephrology (ASN) Kidney Week 2022, 3-6 November 2022, Orlando, Florida, USA.